Dr Laurent Désaubry is a CNRS research director in the University of Strasbourg in France. After a Ph.D. degree in medicinal chemistry and postdoctoral internship at SUNY at Stony Brook (USA) he joined CNRS as Research Senior Scientist at the University of Strasbourg. He was promoted CNRS research director (corresponds to full professor) in 2014, and was appointed adjunct professor at Tianjin University of Science and Technology from 2015 to 2019. He has published more than 110 publications and is serving as an editorial board member of Frontiers in Chemistry, Medicinal Chemistry, Journal of Oncology Research and Treatments,The Open Medicinal Chemistry Journal, Current Chinese Chemistry and International Journal of Molecular Science.
- Development of new cardioprotective non-peptide agonists of prokineticin receptor 1 (PKR1). Cardiac dysfunction leading to heart failure can result from anticancer treatments. As a member of the European ERA-NET consortium in Cardio-Oncology, we are developing new PKR1 agonists to protect the heart against these adverse effects. Publications on cardioprotective PKR1 agonists with graphical abstracts.
- Development of anticancer eIF4A inhibitors.The helicase eiF4A belongs to the eIF4F complex that regulates cap-dependent mRNA translation and represents an emerging target in oncology. An aberrant activity of this complex is observed in many cancers, contributing to resistance to cancer treatments. We are developing new eIF4A to treat cancers resistant to chemotherapies, targeted therapies and immune checkpoint inhibitors. Publications on eIF4A inhibitors without graphical abstracts.
- Development of prohibitins modulators. Prohibitins-1 and -2 (PHB1 and PHB2) are scaffold that regulate many signaling proteins. With our collaborators, we are currently developing several classes of prohibitin ligands against cancers, the adverse effects of anticancer treatments and immune disorders. Publications on prohibitins modulators with graphical abstract.
- Organic chemistry. As part of our projects, we have to develop new reactions in organic synthesis. In each instance, the methodology development represents the investigation of chemistry projected as a key step in the synthesis of new drugs related to the projects presented above. Publications in organic chemistry with graphical abstract.